Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.